ISHITA DRUGS & INDUSTRIES LTD. SHARE PRICE [LIVE]

NSE

₹ N/A

BSE

₹59.95

NSE

BSE Click here to view BSE data

Live Chart

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Open:
High:
Low:

MKT Cap:
52-wk High:
52-wk Low:

Prev close:
P/E:
Div yield:

5 MIN 10 MIN 15 MIN 30 MIN 60 MIN 2 HR 1 D 1 WK 1 M

NEUTRAL

ISHITADR

Fundamental analysis

What is not working for the company?

Stock

Sector

Sensex

Name	Mar 21	Dec 20

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000

in ISHITA DRUGS & INDUSTRIES LTD.

Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %

ISHITADR News

Frequently Asked Questions

What is the Share price of ISHITA DRUGS & INDUSTRIES LTD. (ISHITADR)?

ISHITA DRUGS & INDUSTRIES LTD. (ISHITADR) share price as of September 30, 2022, on BSE is Rs 59.95 (BSE).

Can I buy ISHITA DRUGS & INDUSTRIES LTD. (ISHITADR) shares?

Yes, You can buy ISHITA DRUGS & INDUSTRIES LTD. (ISHITADR) shares by opening a Demat account with Angel One.

How do I buy ISHITA DRUGS & INDUSTRIES LTD. (ISHITADR) from Angel One?

ISHITA DRUGS & INDUSTRIES LTD. (ISHITADR) share can be brought through the following modes:

Direct investment: You can buy ISHITA DRUGS & INDUSTRIES LTD. (ISHITADR) shares by opening a Demat account with Angel One.
Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to ISHITA DRUGS & INDUSTRIES LTD. (ISHITADR) shares.

In which sector do ISHITA DRUGS & INDUSTRIES LTD. (ISHITADR) belong?

ISHITA DRUGS & INDUSTRIES LTD. (ISHITADR) belongs to Pharma.

About ISHITADR

Today's live share price for ISHITA DRUGS & INDUSTRIES LTD. is NSE: N/A, BSE: ₹ 59.95 with a current market capitalization of .

Ishita Drugs & Industries was incorporated in Feb.'92 by Jagdish Agarwal. The company set up a project to manufacture bulk drugs at Sanand, in the Ahmedabad district of Gujarat with an installed capacity of 408 tpa. Commercial production commenced in Jan.'95. Recession in some international markets and intense dumping of the Chinese exporters of the bulk drugs originally planned in the product range, necessiated a review by the company of its production programme and product range. It decided to undertake production of fluoro-quinolones, the latest broad spectrum anti-bacterials. The company established an in-house R&D laboratory which has developed a highly improved process technology for norfloxacin. The in-house process technology for norfloxacin was implemented in its plant in Oct.'95.